4
Changes in Ownership
Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-22-015799
President & CEO gave up 12,162 shares (to pay taxes)
- President & CEO acquired 52,041 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| KAKKIS EMIL D President & CEO | 2022-03-01 | Shares withheld for taxes | −12,162 | $67.37 | $819,354 | 582,185 | D: show line 1 in the form |
| KAKKIS EMIL D President & CEO | 2022-03-01 | Grant or award | +52,041 | 634,226 | D: show line 2 in the form |
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| KAKKIS EMIL D President & CEO | 2022-03-01 | Grant or award · Stock Option (Right to Buy) | +92,360 | 92,360 | D: show line 3 in the form |
Loading xslF345X03/doc4.xml…